Dapagliflozin: more than just another oral glucose-lowering agent?

Bibliography

• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995 – 2025: prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-31
   PubMed Web of Science ®Google Scholar
• Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract 2010;87:2-3
   PubMed Web of Science ®Google Scholar
• Ong KL, Cheung BM, Wong LY, Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999 – 2004. Ann Epidemiol 2008;18:222-9
   PubMed Web of Science ®Google Scholar
• Harris SB, Ekoe JM, Zdanowicz Y, Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-7
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-72
   PubMed Web of Science ®Google Scholar
• Biesenbach G, Bodlaj G, Pieringer H. Weight gain and metabolic control in newly insulin-treated patients with type 2 diabetes with different insulin regimens. Can J Diabetes 2006;30:384-9
   Google Scholar
• Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-42
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 2010;375:2196-1298
   PubMed Web of Science ®Google Scholar
• Desai SA, Alkhalil A, Kang M, Plasmodial surface anion channel-independent phloridzin resistance in plasmodium falciparum. J Biol Chem 2005;280:16861-7
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009;11:79-88
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucoses transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitor: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85
   PubMed Web of Science ®Google Scholar
• Meng W, Elsworth BA, Nirschl AA, Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-9
   PubMed Web of Science ®Google Scholar
• Han S, Hagan DL, Taylor JR, Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Boulton D, Dapagliflozin, a novel SGTL2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, Dapagliflozin, a novel, selective SGTL2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-19
   PubMed Web of Science ®Google Scholar
• Wilding JP, Norwood P, T'joen C, A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng Y, List J, Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-16
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010;33:2217-24
   PubMed Web of Science ®Google Scholar
• Kipnes M. Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opin Investig Drugs 2009;18:335-48
   PubMed Web of Science ®Google Scholar
• Woo VC. Dapagliflozin: where does it fit in the treatment of type 2 diabetes? Expert Opin Pharmacother 2009;10:2527-35
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008;9:1705-20
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-28
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis ES, Tziomalos K, Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Cur Med Res Opin 2010;26:713-19
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ, Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 205;366:1059-62
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JL, Daniels SR, American Heart Association; National Heart, Lung and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung and Blood Institute scientific statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association, World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Horvath K, Jeitler K, Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev 2009;(3):CD007654, doi: 10.1002/14651858.CD007654.pub2
   Google Scholar
• De Ferranti SD, Rifai N. C-reactive protein: a non-traditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007;16:14-21
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Mikhailidis DP. C-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin 2008;24:75-8
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15:3179-92
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem 2009;9:1291-7
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Elisaf MS, Mikhailidis DP. Lipid abnormalities and cardiovascular risk in the elderly. Curr Med Res Opin 2008;24:653-7
   PubMed Web of Science ®Google Scholar
• Windler E, Schoffauer M, Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab Vasc Dis Res 2007;4:136-42
   PubMedGoogle Scholar
• Athyros VG, Mikhailidis DP, Kakafika AI, Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 2007;8:483-8
   Google Scholar
• Reasner CA. What is the most effective strategy for managing diabetic dyslipidemia? Atheroscler Suppl 2005;6:21-7
   PubMed Web of Science ®Google Scholar
• Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 2005;11:4125-32
   PubMed Web of Science ®Google Scholar
• Dimitroula HV, Hatzitolios AI, Karvounis HI. The role of uric acid in stroke: the issue remains unresolved. Neurologist 2008;14:238-42
   PubMed Web of Science ®Google Scholar
• Strasak A, Ruttmann E, Brant L, Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008;54:273-84
   PubMed Web of Science ®Google Scholar
• Strasak AM, Kelleher CC, Brant LJ, Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008;125:232-9
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Mikhailidis DP, Tziomalos K, Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007;71:1120-7
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, Pleiotropic effects of statins: clinical evidence. Curr Pharm Des 2009;15:479-89
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Liberopoulos EN, Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
   PubMed Web of Science ®Google Scholar
• Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
   PubMed Web of Science ®Google Scholar
• Tsouli SG, Liberopoulos EN, Mikhailidis DP, Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293-301
   PubMed Web of Science ®Google Scholar
• Lowe GD. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol 2006;133:232-50
   Google Scholar
• Peer AK, Hoosen AA, Seedat MA, Vaginal yeast infections in diabetic women. S Afr Med J 1993;83:727-9
   PubMed Web of Science ®Google Scholar
• Jeremy JY, Mikhailidis DP, Dandona P. The rat urinary bladder produces prostacyclin as well as other prostaglandins. Prostaglandins Leukot Med 1984;16:235-48
   PubMedGoogle Scholar
• Khan MA, Thompson CS, Mumtaz FH, Role of prostaglandins in the urinary bladder: an update. Prostaglandins Leukot Essent Fatty Acids 1998;59:415-22
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Jeremy JY, Dandona P. Urinary bladder prostanoids: their synthesis, function and possible role in the pathogenesis and treatment of disease. J Urol 1987;137:577-82
   PubMed Web of Science ®Google Scholar